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Abstract
Remyelination is a regenerative process that is essential to recover saltatory conduc-
tion and to prevent neurodegeneration upon demyelination. The formation of new 
myelin involves the differentiation of oligodendrocyte progenitor cells (OPCs) to-
ward oligodendrocytes and requires high amounts of cholesterol. Astrocytes (ASTRs) 
modulate remyelination by supplying lipids to oligodendrocytes. Remarkably, remy-
elination is more efficient in grey matter (GM) than in white matter (WM), which 
may relate to regional differences in ASTR subtype. Here, we show that a feeding 
layer of gmASTRs was more supportive to in vitro myelination than a feeding layer 
of wmASTRs. While conditioned medium from both gmASTRs and wmASTRs ac-
celerated gmOPC differentiation, wmOPC differentiation is enhanced by secreted 
factors from gmASTRs, but not wmASTRs. In vitro analyses revealed that gmASTRs 
secreted more cholesterol than wmASTRs. Cholesterol efflux from both ASTR types 
was reduced upon exposure to pro-inflammatory cytokines, which was mediated via 
cholesterol transporter ABCA1, but not ABCG1, and correlated with a minor reduc-
tion of myelin membrane formation by oligodendrocytes. Surprisingly, a wmASTR 
knockdown of Fdft1 encoding for squalene synthase (SQS), an enzyme essential for 
the first committed step in cholesterol biosynthesis, enhanced in vitro myelination. 
Reduced secretion of interleukin-1β likely by enhanced isoprenylation, and increased 
unsaturated fatty acid synthesis, both pathways upstream of SQS, likely masked the 
effect of reduced levels of ASTR-derived cholesterol. Hence, our findings indicate 
that gmASTRs export more cholesterol and are more supportive to myelination than 
wmASTRs, but specific inhibition of cholesterol biosynthesis in ASTRs is beneficial 
for wmASTR-mediated modulation of myelination.
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1  | INTRODUC TION
Multiple sclerosis (MS) is a demyelinating disease of the central ner-
vous system (CNS) characterized by recurring inflammation, loss of 
oligodendrocytes (OLGs) and myelin, astrogliosis, remyelination fail-
ure, and neuronal loss (Compston & Coles, 2008; Reich, Lucchinetti, 
& Calabresi, 2018). Most therapies for MS do not directly aim to 
promote remyelination, but are rather immunomodulatory, reduc-
ing the number and severity of attacks (Plemel, Liu, & Yong, 2017). 
Remyelination is a regenerative process in which new myelin mem-
branes are formed and which is not only essential to recover sal-
tatory conduction, but also to prevent neurodegeneration (Franklin 
and ffrench-Constant 2008; Fünfschilling et al., 2012; Irvine & 
Blakemore, 2008; Lee et al., 2012). MS lesions are present in both 
grey matter (GM) and white matter (WM) with GM remyelination 
being more pronounced than WM remyelination (Chang et al., 2012; 
Strijbis, Kooi, Valk, & van der, Geurts, 2017). Likewise, regional dif-
ferences in remyelination efficiency are observed in experimental 
toxin-induced demyelination models, where remyelination in the 
cortex, a GM area, is faster and more robust than remyelination in 
the corpus callosum, a WM area (Bai et al., 2016). Revealing the un-
derlying mechanism of this apparent discrepancy between GM and 
WM remyelination may identify novel targets for therapy that pro-
mote remyelination.
In experimental models, remyelination proceeds via differen-
tiation of oligodendrocyte progenitor cells (OPCs) to myelinating 
OLGs. Recent findings indicate that grey matter OPCs (gmOPCs) 
and white matter OPCs (wmOPCs) intrinsically differ (Lentferink, 
Jongsma, Werkman, & Baron, 2018; Viganò, Möbius, Götz, & 
Dimou, 2013). GmOPCs are less mature and more responsive to mi-
togens than wmOPCs (Lentferink et al., 2018), possibly rendering 
gmOPCs better equipped for remyelination (Moyon et al., 2015). In 
addition, wmOPCs are more susceptible to the detrimental effects 
of inflammatory mediators such as interferon-γ (IFNγ, (Lentferink 
et al., 2018)). Astrocytes (ASTRs) play an important role in tran-
sient remodeling of the local signaling environment to facilitate re-
myelination upon CNS demyelination (Gudi, Gingele, Skripuletz, & 
Stangel, 2014; Jong, Wang, Oomkens, & Baron, 2020). Therefore, 
in addition to regional differences in OPCs, ASTRs from different 
brain regions may also contribute to regional differences in remy-
elination efficiency. Indeed, the cellular composition of GM and 
WM differ in the type of ASTRs that are present. More specifi-
cally, protoplasmic ASTRs are present in GM and fibrous ASTRs 
mainly reside in WM (Matyash & Kettenmann, 2010; Oberheim, 
Goldman, & Nedergaard, 2012; Schitine, Nogaroli, Costa, & Hedin-
Pereira, 2015). These ASTR subtypes are morphologically and func-
tionally distinct, that is, protoplasmic ASTRs are morphological 
more complex and ensheath synapses, whereas fibrous ASTRs are 
specialized in providing structural support to myelinated axons and 
interact with the nodes of Ranvier (Oberheim et al., 2012). A dense 
astroglial scar is mainly formed in WM MS lesions and consists of 
persistent locally deposited extracellular matrix molecules, including 
proteoglycans and fibronectin that impair remyelination (reviewed 
in de Jong et al., 2020). While the role of ASTRs in remyelination in 
MS is still debated, a strong correlation exists between severe reac-
tive glial scar formation and remyelination failure (Nair, Frederick, & 
Miller, 2008; Nash, Ioannidou, & Barnett, 2011). Hence, ASTRs from 
GM and WM may distinctly contribute to remyelination efficiency 
in MS lesions.
When OLGs are unable to produce cholesterol during CNS de-
velopment myelin formation is reduced, while there is no difference 
in the ratio of cholesterol to other lipids incorporated in myelin 
(Saher et al., 2005). This indicates that cholesterol is rate-limiting 
for myelin membrane growth and an indispensable lipid component 
of myelin membranes. ASTRs are the main suppliers of cholesterol 
in the CNS (Camargo et al., 2012, 2017; Dietschy & Turley, 2004; 
Nieweg, Schaller, & Pfrieger, 2009; Pfrieger, 2003) and likely sup-
ply cholesterol to OLGs via lipoprotein particles (Saher et al., 2005). 
Although OPCs synthesize more cholesterol upon toxin-induced 
demyelination (Voskuhl et al., 2019), remyelination may also benefit 
from ASTR-derived cholesterol (Camargo et al., 2012). Indeed, both 
cholesterol supplementation and enhancing cholesterol efflux in tox-
in-induced demyelination models, accelerates OPC differentiation 
and remyelination in the corpus callosum, emphasizing a role of hor-
izontal cholesterol transfer for remyelination (Berghoff et al., 2017; 
Cantuti-Castelvetri et al., 2018). In addition, when remyelination is 
impaired, such as in experimental autoimmune encephalomyelitis 
and in MS, genes encoding for enzymes involved in cholesterol pro-
duction, including Hmcgs1, Fdps, and Fdft1, are decreased in ASTRs 
(Itoh et al., 2018). Here, we aimed to address whether gmASTRs and 
wmASTRs differ in cholesterol production and/or efflux and thereby 
distinctly modulate myelination. Our findings revealed that although 
the availability of ASTR-derived cholesterol may play a role in OPC 
maturation, downregulation of committed cholesterol biosynthesis 
in wmASTRs but not gmASTRs, unexpectedly led to increased my-
elination in vitro.
2  | MATERIAL S AND METHODS
2.1 | Primary cell cultures
Animal protocols were approved by Animal Ethics Committee of the 
University of Groningen (the Netherlands, 16504-01-02). All animals 
were used for cell culture experiments and carried out in accordance 
with the European Directive (2010/63/EU) on the protection of ani-
mals used for scientific purposes. Timed-mated female Wister rats 
were purchased from Harlan (RCCHan:WIST, RRID:RGD_5508396) 
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or Charles River (CRL:WI(WU), RRID:RGD_2312472) and kept under 
standardized temperature and humidity and a 12 hr light–dark cycle 
with water and food ad libitum in standard cages (one pregnant fe-
male rat or one female rat with pups per cage). A total of approxi-
mately 30 pregnant female rats were used. The dissected brains or 
spinal cords from 4 to 12 newborn rats (both genders) of one litter 
were pooled and considered as one independent cell culture prepa-
ration. There were no exclusion criteria predetermined, the study 
was exploratory and not pre-registered. Cell treatments were not 
performed in a blinded manner, and the number of experiments was 
not predetermined.
2.1.1 | Oligodendrocytes
Newborn rats (postnatal day 1–3) were decapitated without anes-
thesia. Primary OPCs were isolated from the cortex (GM, referred 
to as gmOPCs) and non-cortical parts (referred to as wmOPCs, WM 
tracts including corpus callosum, mixed GM and WM tracts, includ-
ing hippocampus and thalamus, and deep GM parts, including basal 
ganglia), of forebrains using a shake-off procedure as described 
(Baron, Shattil, & ffrench-Constant C., 2002; Bsibsi, Nomden, Noort, 
& van, Baron W., 2012; Lentferink et al., 2018). Upon 12–14 days in 
mixed glial cultures, contaminating microglia were removed from the 
confluent ASTR layer by a pre-shake at 150 rpm on an orbital shaker 
(Innova 4,000, New Brunswick) for one hour at 37°C. To obtain the 
more firmly attached OPCs, flasks were shaken at 240 rpm overnight 
at 37°C. The detached OPCs were further purified by differential 
adhesion on non-tissue culture dishes for 15–20 min. The enriched 
OPC fraction contained 95%–97% OPCs (Olig2-positive, Millipore, 
RRID:AB_570666), less than 1% microglia (IB4-positive, Invitrogen, 
I21412), 1%–3% ASTRs (glial fibrillary acidic protein (GFAP)-positive, 
DAKO, RRID:AB_10013382) and less than 1% neurons (TuJ1-
positive, kind gift of Dr A. Frankfurter, University of Virginia). OPCs 
were cultured on 13-mm poly-L-lysine (5 µl/ml; Sigma, P2636)-
coated glass coverslips in 24-well plates at a density of 35,000 
cells/well (gmOPCs) or 40,000 cells/well (wmOPCs) in defined Sato 
medium (Lentferink et al., 2018). OPCs were synchronized to early 
OPCs by 10 ng/ml platelet-derived growth factor-AA (PDGF-AA; 
Peprotech, 100–13) and 10 ng/ml human fibroblast growth factor-2 
(FGF-2; Peprotech, 100–18). After two days, growth factors were 
removed and OPCs were allowed to differentiate in Sato medium 
supplemented with 0.5% fetal bovine serum (FBS, Capricorn, FBS-
12A) for three or six days in the absence or presence of astrocyte-
conditioned medium (ACM, 1:1).
2.1.2 | Astrocytes
After obtaining OPCs, remaining ASTRs of the mixed glial cultures, 
were shaken at 240 rpm overnight at 37°C, passaged once by trypsi-
nization, transferred to 162 cm2 flasks (Corning, 3,150) and cultured 
in ASTR medium [100 U/ml penicillin and 100 μg/ml streptomycin 
(Gibco, 15,140,122, 4 mM L-glutamine (Invitrogen, 25030-123), 
10% heat-inactivated FBS (Bodinco, 4005-BDC-0814) in DMEM 
(Gibco, 49,165,039)]. This yielded a highly pure ASTR population 
for both gmASTRs and wmASTRs (>97% GFAP-positive). For im-
munocytochemistry, ASTRs were plated on poly-L-lysine-coated 
glass coverslips at a density of 5.0 × 104 cell/well in a 24-well plate. 
For cholesterol assays and qPCR assays, ASTRs were cultured at a 
density of 1.0 × 106 cells/well in six-well plates in ASTR medium. 
For cholesterol assays, cells were washed after 24 hr and serum-free 
ASTR medium was added. In case of lentiviral transduced ASTRs, 
defined SATO medium was added. ASTRs were either left untreated 
or treated for 24 hr with either Toll-like-receptor (TLR) 3 agonist 
polyinosinic-polycytidylic acid (Poly(I:C), 50 μg/mL, Sigma, P1530), 
TLR4 agonist lipopolysaccharide (LPS, 200 ng/ml, Sigma, L4391), 
or a combination of the following pro-inflammatory cytokines: 
IFNγ (500 IU/mL, Peprotech, 400–20), interleukin-1β (IL1β, 1 ng/
ml, Peprotech, 400-01), and tumor necrosis factor-α (TNFα, 10 ng/
ml, Peprotech, 400-14). To inhibit cholesterol transporters, either 
ATP-binding cassette transporter (ABC) A1 inhibitor glibenclamide 
(0.1 mM, Sigma, G0639) or ABCG1 inhibitor thyroxine (T4, 50 µM, 
Sigma, T1775) were added one hour before addition of cytokines. 
For immunoblot analysis, 1.0 × 106 cells were plated on 10 cm dishes 
(Corning, 430,167). The cells were either left untreated or treated 
with a mixture of pro-inflammatory cytokines (IFNγ, IL1β, and TNFα) 
for 24 hr at 37°C. For collection of ACM, cells were plated in 6-well 
plates at 1.0 × 106 cells/well in ASTR medium. ASTRs were either 
left untreated or treated with a mixture of pro-inflammatory cy-
tokines IFNγ, IL1β, and TNFα, or cultured in the presence of 10 μg/
ml bodipy-cholesterol (Avanti, 8110255, Hölttä-Vuori et al., 2008). 
After 24 hr, cells were washed and cultured for another 24 hr in 
Sato medium. ACM was collected, filtered using a 0.45 µm filter (GE 
Healthcare, 10462100) and stored at −20˚C.
2.1.3 | Spinal cord cultures
Myelinating spinal cords were generated from 15-days old rat em-
bryos as described with minor modifications (Sorensen, Moffat, 
Thomson, & Barnett, 2008). Pregnant female rats were sacrificed 
with overdoses of euthasol via IC injection when under anesthesia 
(5% isoflurane), after which the embryos were removed and de-
capitated. After removal of the meninges from the isolated spinal 
cords, tissue was mechanically dissociated in Leibowitz L-15 me-
dium (Sigma, L4386) followed by enzymatic digestion with a mix-
ture of trypsin (2.5%, Sigma, T8253) and DH liberase (2.5 mg/ml, 
Roche, 05401054001) for 20 min at 37°C. The enzymatic reac-
tion was stopped by addition of Soybean trypsin inhibitor solution 
[0.52 mg/ml soybean trypsin inhibitor (Sigma, T6522), 0.04 mg/ml 
bovine pancreas DNase (Roche, 10104159001) and 3 mg/ml fatty 
acid-depleted bovine serum albumin (BSA, Sigma, A4919) made up 
in Leibovitz's L15 medium]. The cells were centrifuged for 7 min at 
180 g, followed by resuspension in plating medium consisting of 50% 
DMEM (1,500 mg/L glucose, Gibco, 31885023), 25% horse serum 
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(Invitrogen, 26050088), 25% HBSS with calcium and magnesium 
(Invitrogen, 14025-100), and 2 mM L-glutamine. Cells were plated on 
13-mm glass coverslips (VWR, 631-0150) in 24-well plates at a den-
sity of 200,000 cells/well or in an 8-well permanox chamber slide 
(Nunc, 177445) at 160,000 cells/well in respectively 500 μl or 200 μl 
plating medium. The coverslips and chamber slides contained a con-
fluent feeding layer of gmASTRs or wmASTRs (80,000 cells/13-mm 
coverslip; 64,000 cells/chamberslide well). After 2 hr, the volume of 
the medium was doubled with growth medium [DMEM 4,500 mg/L 
glucose, (Gibco, 49,165,039) supplemented with 5 mg/ml holotrans-
ferin (Sigma, T0665), 20 mM putrescine (Sigma, P5780), 4 µM pro-
gesterone (Sigma, P-0130), 6 µM selenium (Sigma, S5261), 10 ng/ml 
biotin (Sigma, B4639), 50 nM hydrocortisone (Sigma, H0135), and 
10 μg/mL insulin (Sigma, I1882)], and when cultured on permanox 
chamber slides supplemented with 27.5 µM 2-mercaptoethanol 
(Gibco, 21985023). Every two to three days, half of the medium was 
replaced by new growth medium. Insulin was omitted from growth 
medium from 12 days in cultures onwards. Cultures were analyzed 
after 28 days in culture.
2.2 | Lentivirus production and transduction
For production of lentiviral particles, the constructs (pLKO.1-puro 
Sigma mission shRNA, construct SHCLNG-NM_010191, sequence 
TRCN0000099191, for rat Fdft1 shRNA, or SHC002 for control 
scrambled shRNA; 5 µg), packaging, and envelope plasmids (500 ng 
pMD2-VSVG; 5 µg pCMV-R8.91) were transfected into the HEK293T 
packaging cell line using Fugene (Promega, E2311) according to 
manufacturer's instructions. After 16 hr, medium was changed to 
mixed glial culture medium [100 U/ml penicillin, 100 μg/ml strepto-
mycin, 4 mM L-glutamine, 10% (v/v) FBS in DMEM]. Viral particles 
were harvested in mixed glial culture medium for 48 hr and filtered 
through polyvinylidene fluoride (PVDF) membrane-based 0.45-μm 
filter (GE Healthcare, 514–0226) and either used immediately or 
stored at −80°C. Lentiviral particles were added overnight to ASTRs 
(1:3 with ASTR medium) in the presence of hexadimethrine bromide 
(Polybrene, 8 μg/mL, Sigma, TR1003). Cells were washed and either 
used for spinal cord cultures or left for five days for qPCR analysis, 
cholesterol assays and production of ACM.
2.3 | Cholesterol assays
2.3.1 | Lipid extraction
Lipids from cells and medium were extracted using the Bligh and 
Dyer method (Bligh & Dyer, 1959; Klappe, Hummel, & Kok, 2013). 
Briefly, a methanol-chloroform-mixture (1:2; chloroform, Merck, 
1.02445; methanol, Biosolve, 136806) was added and the samples 
were centrifuged at 820 g for 5 min. The lower phase was collected 
and the upper phase was further processed by adding chloroform 
(1:1). After centrifugation at 820 g for 5 min, the lower phase was 
added to previous collected lower phase and dried with a vacuum 
centrifuge and/or heating to 60°C. To determine cholesterol and 
phosphate levels, the dried lipid extracts of the cell samples were 
dissolved in 0.5 ml chloroform mixture (1:1), split and dried with the 
vacuum centrifuge.
2.3.2 | Cholesterol levels
Free cholesterol levels in cells (intracellular) and medium (extracel-
lular) were quantified using a fluorescence-based enzymatic method 
(Gamble, Vaughan, Kruth, & Avigan, 1978; Klappe et al., 2013). 
The dried lipid extracts were dissolved in ethanol and a mixture of 
0.63 mg/ml parahydroxy-phenylacetic acid (Sigma, H50004), 0.2 M 
phosphate buffer (pH 7.4), 20 mM sodium cholate (Sigma, C9282), 
0.5% Triton-X-100, water, cholesterol oxidase (0.15 U/mL, Sigma, 
9028-76-6) and peroxidase (0.95 U/mL, Sigma, P6140) was added 
and incubated for 20 min in the dark. Of note, cholesterol oxidase is 
sensitive to cholesterol, and oxidizes other sterols with a much lower 
rate (MacLachlan, Wotherspoon, Ansell, & Brooks, 2000). Standard 
concentrations of 0–29 nmol cholesterol were also included. 
Fluorescence was measured with an excitation of 325 nm and an 
emission of 415 nm (PerkinElmer instruments LS 55). The cholesterol 
efflux was calculated using the formula: efflux = extracellular cho-
lesterol levels/ (intracellular + extracellular cholesterol levels).
2.3.3 | Phosphate determination
As an internal control, the amount of phosphate in each sample was 
determined serving as an indication of the lipid amount in the sample 
(Smith et al., 1985). To this end, a standard curve was prepared using 
0–320 nmol phosphate. Then, 0.2 ml of 70% perchloric acid (Sigma, 
244252) was added and the samples were heated to 180°C for 
30 min. After cooling down, 2 ml of molybdate reagent (ammonium 
heptamolybdate tetrahydrate (Sigma, 12054–85–2), concentrated 
sulfuric acid (Sigma, 7664-93-9), water) and 0.25 ml of freshly made 
10% ascorbic acid (Wako Pure Chemical, 323-44822) were added 
and the samples were heated to 95°C for ten minutes. To stop the re-
action, the samples were placed in ice and absorbance was measured 
at 812 nm (μQuant, Bio-Tek). For intracellular cholesterol levels, the 
amount of cholesterol was normalized to phosphate, that is, the ratio 
of cholesterol to phosphate was calculated (nmol/nmol).
2.4 | Western blot analysis
For immunoblots of ABCA1 and ABCG1, cells were washed 
with phosphate-buffered saline (PBS) and scraped in lysis buffer 
[1% Triton X-100, 50 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA, 
and protease inhibitor cocktail (Roche, 11836153001), pH 7.4]. 
Protein concentration was determined by a detergent-compatible 
protein determination assay (Bio-Rad, 500–0116) according to 
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manufacturer's instructions using BSA as a standard. Equal amounts 
of proteins (50 μg) were loaded onto 7.5% SDS-polyacrylamide 
gels. For detection of IL1β in medium, equal volumes (80 µl) were 
loaded onto 15% SDS-polyacrylamide gels. After gel electropho-
resis, proteins were transferred onto PVDF membranes (Millipore, 
IPFL00010) via wet transfer. After blocking the membrane for one 
hour with Odyssey blocking buffer (1:1 in PBS, Li-Cor Biosciences, 
927-40003), membranes were incubated with primary antibod-
ies against ABCA1 (monoclonal mouse anti-ABCA1, 1:500, Novus 
Biologicals, RRID:AB_10002789), ABCG1 (polyclonal rabbit anti-
ABCG1, 1 μg/ml, Novus Biologicals, RRID:AB_10125717), actin 
(monoclonal mouse anti-β-actin; 1:2000, Sigma, RRID:AB_476744), 
or IL1β (monoclonal hamster anti-IL1β, 1:200, Santa Cruz, 
RRID:AB_627791) overnight at 4°C. After washing with PBS con-
taining 0.1% Tween-20, IRDye-conjugated secondary antibodies (Li-
Cor Biosciences, Lincoln, RRID:AB_10956588, RRID:AB_10956166, 
RRID:AB_621843, and RRID:AB_621842; 1:3,000) were incubated 
for one hour. For IL1β, an additional incubation step with a rabbit-
anti-hamster linker antibody (Jackson, RRID:AB_2339572) was con-
ducted, before secondary antibodies were applied. The bands were 
visualized with the Odyssey Imaging System (Li-Cor). For cell lysates, 
the expression of each protein was calculated relative to the amount 
of β-actin with densitometry using FIJI (ImageJ).
2.5 | Immunocytochemistry
2.5.1 | Primary cell cultures
The cells were fixed with 4% paraformaldehyde (VWR, 1.04005) for 
15 min at 20 ℃, and permeabilized with ice-cold methanol for 10 
min. Non-specific antibody binding was blocked with 4% BSA for 
30 min after which cells were incubated with primary antibodies 
anti-myelin basic protein (MBP, 1:250, Serotec, RRID:AB_325004) 
or anti-GFAP (1:500) at 20 ℃. The cells were rinsed three times 
with PBS before the appropriate Alexa Fluor©-conjugated second-
ary antibodies (1:500, Thermo Fisher Scientific, RRID:AB_2534093, 
RRID:AB_2534125) were added together with DAPI (1 μg/ml, nu-
clear stain, Sigma, D9542) for 30 min at 20 ℃. After three washes 
with PBS, coverslips were mounted using mounting medium (Dako, 
S302580–02). Cells were analyzed using a conventional immuno-
fluorescence microscope (Leica DMI 6,000 B) equipped with Leica 
Application Suite Advanced Fluorescence software. In each inde-
pendent experiment, approximately 150–250 cells per coverslip 
were scored for the percentage of MBP-positive cells of DAPI-
stained cells (differentiation), or for the percentage of MBP-positive 
cells that form myelin membranes (myelin membrane formation).
2.5.2 | Spinal cord cultures
Spinal cord cultures were fixed with 4% paraformaldehyde for 30 min, 
and blocked and permeabilized with 0.1% Triton X-100 in 4% BSA in 
PBS for 45 min. After three washes with PBS, cells were incubated 
for 90 min with anti-MBP (1:250) and anti-neurofilament-H (NF, pol-
yclonal chicken anti-neurofilament, 1:5,000, EnCor Biotechnology 
Inc.,RRID:AB_2149761) antibodies at 20 ℃. Cells were rinsed three 
times with PBS before the appropriate FITC-conjugated secondary 
antibodies (1:50, Jackson Immunolaboratories, RRID:AB_2338189) 
or Alexa Fluor©-conjugated secondary antibodies (1:500, 
RRID:AB_2534074, RRID:AB_2534098) were added together with 
DAPI for 45 min at 20 ℃. Coverslips and slides were mounted with 
mounting medium (Dako). Samples were imaged using either a con-
ventional immunofluorescence microscope (Leica DMI 6,000 B) or 
a confocal microscope (TCS SP2 or SP8 AOBS Microscope, Leica 
Microsystems) using Leica Software. The percentage of myelinated 
axons was either calculated in ImageJ as an area in pixels in each 
image occupied by both myelin and axons divided by the axonal 
density (Qin et al., 2017; Stancic et al., 2012) or in MATLAB using 
software programmed to recognize only linear structures, thus 
only including myelin and axons and excluding OLG cell bodies (Qin 
et al., 2017). In each experiment, five images per coverslip and one 
to two coverslips per condition were analyzed.
2.6 | qPCR analysis
The cells were scraped in RNA protect (Qiagen, 76526) and RNA 
was isolated using an RNA-isolation kit (Isolate II RNA Micro Kit; 
Bioline, BIO-52075) according to manufacturer's instructions. RNA 
(1 μg) was reverse transcribed in the presence of oligo(dT)12–18 
(Invitrogen, 18418012) and dNTPs (Invitrogen, 10297018) with 
M-MLV reverse transcriptase (Invitrogen, 28025013). mRNA lev-
els of Fdft1, Fasn, Srebf1c, and Srebf2 were measured by real-time 
TA B L E  1   Primer sequences used for qPCR
gene Forward primer Reverse primer
Product 
size (bp)
Eef1a1 5’-GATGGCCCCAAATTCTTGAAG−3’ 5’-GGACCATGTCAACAATTGCAG−3’ 52
Fdft1 5’-TCTACAACCTGCTGCGATTC−3’ 5’-GCGACTGGTCTGATCAAGATAC−3’ 119
Fasn 5’-GGCAATACCCGTTCCCTGAA−3’ 5’-GGCAATACCCGTTCCCTGAA−3’ 92
Hprt1 5’-GACTTGCTCGAGATGTCA−3’ 5’-TGTAATCCAGCAGGTCAG−3’ 102
Srebf1c 5’-GGAGCCATGGATTGCACATTT−3’ 5’-CCAGCATAGGGGGCATCAAA−3’ 92
Srebf2 5'-GGGCTGTCGGGTGTCATGG−3' 5'-GGCAATACCCGTTCCCTGAA−3' 105
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quantitative reverse transcriptase PCR (qPCR) using Absolute 
qPCR SYBR Green Master Mix (BioRad, 172-5124) in a Step-One 
Plus Real-Time PCR machine. Each measurement was performed 
in triplicate and amplification data was processed using the 
LinRegPCR method (Ramakers, Ruijter, Lekanne, & H., Moorman 
A. F. M., 2003; Ruijter et al., 2009). Primer sequences are shown in 
Table 1. Expression was normalized to housekeeping genes Eef1a1 
or Hprt1.
2.7 | Statistical analysis
Data are expressed as mean ± standard error of the mean (SEM) 
of at least three independent cell culture preparation experiments. 
A Shapiro–Wilk normality test was first applied to test the normal 
distribution of the data. When normality failed, a Kruskal–Wallis 
test was used to test for statistical significance. When normality 
passed and when comparing absolute values between groups (i.e., 
gmASTRs vs. wmASTRs) statistical significance was assessed using 
a paired two-sided t-test. When normality passed and when rela-
tive groups were compared to control [i.e., non-conditioned medium 
(NCM), control gmASTRs, control wmASTRs, control gmACM, or 
control wmACM], statistical analysis was performed with a one-
sample t-test, with the indicated control set to 1 in each independ-
ent cell culture experiment. A paired student's t-test was used to 
test for differences between effects of wmACM and gmACM on 
OPC differentiation (#) with NCM was set to 1 in each independent 
cell culture experiment. A one-way ANOVA with a Šidák multiple 
comparisons post-test was performed to test for differences be-
tween multiple different treatments. Statistics were performed 
using GraphPad Prism 6.0. In all cases, p-values of < .05, <0.01, 
and < .001 were considered significant and indicated with *, ** and 
*** or #, ##, and ###, respectively.
3  | RESULTS
3.1 | Cultured grey matter astrocytes are more 
supportive to myelination than cultured white matter 
astrocytes
To examine whether gmASTRs and wmASTRs distinctly modulate 
myelination efficiency, an in vitro myelinating system of embryonic 
spinal cord cultures that relies on an ASTR feeding layer was em-
ployed (Qin et al., 2017; Sorensen et al., 2008). To this end, ASTRs 
from the cerebral cortex (GM, referred to as gmASTRs) and non-cor-
tical parts (mainly WM, referred to as wmASTRs) of postnatal day 
1–3 rat forebrains were isolated and cultured for at least 21 days in a 
mixed glial culture. The obtained gmASTRs and wmASTRs were pos-
itive for the ASTR marker GFAP (Figure 1a). Consistent with previous 
observations of cultured ASTRs isolated from different brain regions 
at postnatal day 5 (Goursaud, Kozlova, Maloteaux, & Hermans, 2009), 
gmASTRs were more protoplasmic, while wmASTRs adopted a more 
fibrous stellate morphology (Figure 1a). Therefore, regional differ-
ences in morphology are likely acquired even before ASTRs are ma-
ture, that is, ASTRs are considered mature at postnatal day 14–21 
(Bushong, Martone, & Ellisman, 2004; Cahoy et al., 2008), likely 
as ASTRs do not postnatally redistribute (Bayraktar, Fuentealba, 
Alvarez-Buylla, & Rowitch, 2014; Taft, Vertes, & Perry, 2005; Tsai 
et al., 2012). Assessment of the percentage of myelinated axons, as 
determined by a co-labeling of the myelin marker MBP and the ax-
onal marker NF, revealed that the percentage of myelinated axons 
was higher on a feeding layer of gmASTRs than on a feeding layer of 
wmASTRs (Figure 1b and c, p = .018). In monoculture, OPCs readily 
differentiate into MBP-positive OLGs that elaborate myelin mem-
branes. To examine whether the distinct modulation of protoplasmic 
gmASTRs and fibrous wmASTRs on in vitro myelination relates to a 
difference in gmASTR- and wmASTR-derived secreted factors, the 
F I G U R E  1   Grey matter astrocytes are more supportive for in vitro myelination than white matter astrocytes. (a) GFAP 
immunocytochemistry of primary neonatal grey matter (gm) and white matter (wm) astrocytes (ASTRs). (b and c) In vitro myelinating cultures 
that depend on a feeding layer of ASTRs are obtained from 15-day-old rat embryo spinal cord cells and stained for the myelin marker myelin 
basic protein (MBP, green) and the axonal marker neurofilament-H (NF, red). Representative images are shown in (b) and quantification of the 
percentage of myelinated axons in (c) (n = 6 independent cell culture preparations). Note that a feeding layer of gmASTRs is more supportive 
for in vitro myelination than a feeding layer of wmASTRs (p = .018). (d-f) Neonatal wmOPCs (d–f) and gmOPCs (e and f) were differentiated 
for three or six days in the presence of non-conditioned medium (NCM) or ASTR-conditioned medium (ACM) from gmASTRs or wmASTRs. 
MBP immunocytochemistry is performed to assess differentiation (% MBP-positive cells of DAPI-stained cells) and myelin membrane 
formation (% myelin membranes formed by MBP-positive cells). Representative images of MBP-positive wmOLGs (red) in the presence of 
NCM, wmACM or gmACM three days after initiating differentiation are shown in (d) (arrow indicates MBP-positive cells; arrowheads point 
to myelin membranes). Quantification of OPC differentiation in the presence of NCM, wmACM or gmACM is shown in (e) and quantification 
of myelin membrane formation in (f) (n = 4–6 independent cell culture preparations). Note that upon exposure to gmACM but not wmACM, 
wmOPC differentiation is significantly increased three days after initiating differentiation (p = .028) compared to exposure to NCM, while 
gmOPC differentiation is increased upon exposure to both wmACM and gmACM (wmACM p = .002, gmACM p = .037). Bars represent 
absolute values (c) or relative means compared to NCM (e,f), which is set to 1 in each independent experiment. Error bars represent standard 
error of the mean (SEM). Statistical analyses are performed using column statistics with a one-sample t-test (*p < .05) to test for differences 
between ACM treatments and NCM-treated control, while a paired t-test (*p < .05) is used to test for differences between effects of 
gmACM and wmACM (not significant). For wmOPC differentiation absolute values of NCM are 15.7 ± 3.5% after three days and 36.5 ± 9.1% 
after six days and for myelin membrane formation 55.5 ± 5.6% after three days and 63.5 ± 16.9% after six days. For gmOPC differentiation 
absolute values of NCM are 9.0 ± 2.7% after three days and 47.5 ± 6.1% after six days and for myelin membrane formation 47.8 ± 8.9% after 
three days and 84.2 ± 2.1% after six days. Scale bars are 25 µm (a and d) and 50 µm (b)
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effect of astrocyte-conditioned medium (ACM) on OPC differen-
tiation and myelin membrane formation was examined in monocul-
tures. As gmOPCs and wmOPCs distinctly respond to injury signals 
(Lentferink et al., 2018), and as both are present in our in vitro my-
elinating cultures, the effect of ACM from gmASTRs (gmACM) or 
wmASTRs (wmACM) on both gmOPC and wmOPC maturation was 
taken into account. Three days after initiating wmOPC differen-
tiation, exposure to gmACM, but not wmACM, increased the per-
centage of MBP-positive cells (Figure 1e, p = .028) -a read-out for 
OPC differentiation- compared to non-conditioned medium (NCM). 
Moreover, six days after initiating wmOPC differentiation, the per-
centage of MBP-positive cells was reproducibly, but not significantly 
higher in the presence of gmACM than in the presence of wmACM 
(Figure 1e), indicating that gmACM, but not wmACM, enhanced 
wmOPC differentiation. In contrast, three days after initiating 
gmOPC differentiation the percentage of MBP-positive cells was 
significantly enhanced upon exposure to both gmACM and wmACM 
compared to NCM (Figure 1e, wmACM p = .002; gmACM p = .037). 
Remarkably, six days after initiating gmOPC differentiation, the per-
centage of MBP-positive cells was similar at all conditions, indicating 
that both wmACM and gmACM accelerated gmOPC differentiation. 
No significant difference in myelin membrane formation was ob-
served upon gmACM and wmACM treatment of either type of OPC 
at three days or six days after initiating differentiation (Figure 1f). 
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Hence, these findings demonstrated that gmASTRs were more sup-
portive to in vitro myelination than wmASTRs, likely by secreting 
(more) factors that enhanced wmOPC differentiation. As ASTRs 
are the most important lipid suppliers in the adult CNS (Camargo 
et al., 2017) and exogenously supplied cholesterol accelerates OPC 
differentiation (Berghoff et al., 2017), we next examined whether 
gmASTRs and wmASTRs differ in their capacity to supply choles-
terol to differentiating OLGs.
3.2 | Grey matter astrocytes secrete more 
cholesterol than white matter astrocytes
Sterol regulatory element-binding proteins (SREBPs) are a fam-
ily of membrane-bound transcription factors that modulate 
the transcription of genes of enzymes that are required for the 
synthesis of cholesterol and unsaturated fatty acids (Shimano 
& Sato, 2017; Shimomura, Shimano, Korn, Bashmakov, & 
Horton, 1998). SREBP-2 drives the transcription of genes 
of enzymes involved in cholesterol biosynthesis (Figure 2a). 
qPCR analysis revealed that mRNA levels of SREBP-2 (Srebf2) 
were higher in cultured gmASTRs than in cultured wmASTRs 
(Figure 2b, p = .003). In addition, cholesterol efflux from gmAS-
TRs was higher than cholesterol efflux from wmASTRs (Figure 2c, 
p = .006), while intracellular levels of cholesterol in gmASTRs 
and wmASTRs were comparable (Figure 2d). Other studies have 
demonstrated that exogenously supplied cholesterol facilitates 
mouse gmOPC differentiation in vitro (Berghoff et al., 2017). 
To confirm this observation for rat wmOPCs, rat wmOPCs were 
differentiated in the presence of cholesterol. Three days after 
F I G U R E  2   Grey matter astrocytes secrete more cholesterol than white matter astrocytes. (a) Schematic overview of several 
intermediates in the cholesterol and unsaturated fatty acid synthesis pathway. SREBP-2 and SREBP-1c are transcription factors, and SQS 
and FASN are enzymes involved in committed cholesterol and unsaturated fatty acid synthesis, respectively. (b) qPCR analysis of Srebf2 
in primary neonatal grey matter (gm) and white matter (wm) astrocytes (ASTRs; n = 3 independent cell culture preparations). (c and d) 
Cholesterol assays on gmASTRs and wmASTRs. Cholesterol efflux is shown in (c) and intracellular cholesterol levels, shown as intracellular 
cholesterol/phosphate ratios, in (d) (n = 16–19 independent cell culture preparations). (e and f) Neonatal wmOPCs were differentiated for 
three days in the absence (ctrl) or presence of 10 μg/ml cholesterol (chol). Myelin basic protein (MBP) immunocytochemistry is performed 
to assess differentiation (e, % MBP-positive cells of DAPI-stained cells) and myelin membrane formation (f, % myelin membranes formed 
by MBP-positive cells; n = 3 independent cell culture preparations). Note that exposure to cholesterol enhances wmOPC differentiation 
(p = .008) and myelin membrane formation (p = .048). (g) wmOPCs were exposed to ACM obtained from ASTRs that were pre-incubated 
with 10 μg/mL bodipy-cholesterol and analyzed three days after initiating differentiation. Note that wmOLGs take up bodipy-cholesterol 
secreted from ASTRs. Bars represent absolute values (c and d) or relative means compared to wmASTRs (b, wm) or untreated wmOLGs (e 
and f, ctrl), which are set to 1 in each independent experiment. Error bars represent standard error of the mean (SEM). Statistical analyses 
are performed using column statistics with a one-sample t-test (*p < .05, **p < .01) to test for differences with wmASTRs (b) or ctrl wmOLGs 
(e and f), while a paired student t-test (**p < .01) is used to test for differences between cholesterol efflux from wmASTRs and gmASTRs. 
Absolute values of ctrl OLGs for OPC differentiation are 20.5 ± 4. 1% and for myelin membrane formation 46.7 ± 6.4%. Scale bar is 10 µm
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initiating differentiation, both wmOPC differentiation (Figure 2e, 
p = .008) and myelin membrane formation (Figure 2f, p = .048) 
were enhanced upon cholesterol treatment. Labeling of ASTRs 
with the fluorescent cholesterol derivative bodipy-cholesterol 
(Hölttä-Vuori et al., 2008), followed by exposure of differentiating 
wmOPCs to ACM, showed that ASTR-derived bodipy-cholesterol 
was taken up by wmOLGs (Figure 2g). Thus, cholesterol efflux was 
higher from gmASTRs, which strongly suggests that the increased 
levels of secreted cholesterol by gmASTRs may add to enhanced 
wmOPC differentiation in the presence of gmACM, but not 
wmACM (Figure 1e). As inflammatory mediators interfere with 
cholesterol efflux (Yin, Liao, & Tang, 2010) and to further explore 
the role of ASTR-derived cholesterol in myelination efficiency, the 
effect of MS-relevant inflammatory mediators on cholesterol ef-
flux from ASTRs was examined next.
3.3 | A mixture of pro-inflammatory cytokines 
reduces cholesterol efflux from grey matter and white 
matter astrocytes
MS is characterized by chronic inflammation (Chang et al., 2012; 
Compston & Coles, 2008; Nair et al., 2008; Park et al., 2019; 
Peterson, Bö, Mörk, Chang, & Trapp, 2001), and as ASTRs re-
spond to inflammatory mediators, the effect of pro-inflammatory 
cytokines and TLR agonists on cholesterol efflux was assessed. 
To this end, gmASTRs and wmASTRs were exposed either to a 
mixture of pro-inflammatory cytokines (IFNγ, IL1β, and TNFα), 
Poly(I:C) or LPS for 24 hr. Poly(I:C) and LPS are agonists for 
TLR3 and TLR4, respectively. Cholesterol efflux from LPS-
treated gmASTRs was significantly reduced (Figure 3a, p = .033). 
Moreover, cholesterol efflux from cytokine-treated gmASTRs 
and wmASTRs was also reduced by 35%–45% compared to the 
respective untreated ASTRs (Figure 3a, wm + cytokines p = .001; 
gm + cytokines p=<0.001). For all ASTR treatments, intracellu-
lar levels of cholesterol were not significantly changed compared 
to the levels in untreated ASTRs (Figure 3b). Exposure to ACM 
obtained from cytokine-treated gmASTRs reproducibly, but not 
significantly reduced myelin membrane formation by wmOLGs 
(Figure 3d, grey bars). In contrast, the percentage of MBP-positive 
cells was not altered compared to exposure to untreated control 
gmACM (Figure 3c, grey bars). Exposure to ACM obtained from 
cytokine-treated wmASTRs did not alter wmOPC differentiation 
and myelin membrane formation (Figure 3c and d, white bars). To 
determine whether the cytokines interfered with cholesterol bio-
synthesis, the mRNA levels of Srebf2 and Fdft1 were examined. 
Fdft1is a gene encoding for squalene synthase (SQS), which is the 
first enzyme in the committed cholesterol biosynthesis pathway 
(Figure 2a). In contrast to previous findings (Memon et al., 1997; 
Park et al., 2016), neither Srebf2 (Figure 3e) nor Fdft1 (Figure 3f) 
mRNA levels were decreased in cytokine-treated gmASTRs and 
wmASTRs. Instead, transcripts of both Fdft1 and Srebf2 seemed to 
increase in cytokine-treated gmASTRs and wmASTRs, indicating a 
potential compensatory mechanism for the decreased cholesterol 
efflux from both types of ASTRs. In line with such a negative feed-
back loop is that Srebf1c mRNA levels were significantly decreased 
in cytokine-treated wmASTRs (Figure 3g, p = .048) and gmASTRs 
(Figure 3g, p = .008). Srebf1c encodes for SREBP-1c, the major 
transcription factor involved in unsaturated fatty acid synthesis 
(Shimano & Sato, 2017) (Figure 2a). Furthermore, mRNA levels 
of Fasn, encoding for the enzyme fatty acid synthase (Figure 2a), 
were significantly reduced in cytokine-treated gmASTRs but not 
cytokine-treated wmASTRs (Figure 3h, p < .001). These findings 
indicate that unsaturated fatty acid production and secretion may 
be reduced in cytokine-treated ASTRs as well and thus may af-
fect ASTR-mediated modulation of myelin membrane formation. 
Hence, the cytokine-induced decrease in cholesterol efflux from 
gmASTRs correlated with a decrease in ASTR-mediated modula-
tion of myelin membrane formation, as well as with a decrease 
in mRNA levels of genes encoding for a transcription factor and 
enzyme involved in unsaturated fatty acid synthesis.
3.4 | Pro-inflammatory cytokines inhibit 
cholesterol efflux from astrocytes via an ABCA1-
dependent pathway
Cholesterol is transported via passive transfer over the plasma 
membrane as well as via facilitated transport (Chen, Zhang, 
Kusumo, Costa, & Guizzetti, 2013). The main transporters of 
cholesterol in ASTRs are ATP-binding cassette transporters A1 
(ABCA1) and G1 (ABCG1) (Chen et al., 2013). To assess whether 
ABCA1 and/or ABCG1 contributed to the cytokine-induced de-
crease in cholesterol efflux from ASTRs, the ABCA1 inhibitor glib-
enclamide (Terao et al., 2011) or the ABCG1 inhibitor thyroxine 
(T4) (Cserepes et al., 2004), were added one hour prior to treat-
ment with the mixture of cytokines. T4, but not glibenclamide, 
significantly inhibited cholesterol efflux from untreated gmASTRs 
and wmASTRs by 40%–50% (Figure 4a, wm + glibencalamide, 
p = .015; gm + T4, p = .029). This is in line with previous find-
ings that ABCG1 is the main cholesterol transporter in ASTRs 
(Karten, 2006). In contrast, glibenclamide, but not T4, prevented 
the cytokine-induced reduction in cholesterol efflux from gmAS-
TRs (Figure 4a, gm + cytokines versus gm + cytokines +gliben-
clamide, p = .027), and reproducibly, but not significantly from 
wmASTRs (Figure 4a, p = .074). Of note, simultaneous treatment 
with both inhibitors was toxic to ASTRs. Western blot analysis re-
vealed that a mixture of pro-inflammatory cytokines significantly 
decreased ABCA1 expression in gmASTRs (Figure 4c,d, gm + cy-
tokines p < .001). In contrast, ABCG1 expression was significantly 
higher in cytokine-treated gmASTRs than in untreated gmASTRs 
(Figure 4c and e, gm + cytokines p = .004). The effect of cytokines 
on ABCA1 and ABCG1 expression in wmASTRs was less pro-
nounced (Figure 4c-e). These findings demonstrate that although 
treatment with pro-inflammatory cytokines decreased ABCA1 ex-
pression and increased ABCG1 expression, the cytokine-induced 
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reduction in cholesterol efflux from gmASTRs, and to a lesser ex-
tent from wmASTRs, depended on ABCA1 activity.
3.5 | Inhibition of committed cholesterol 
biosynthesis in white matter astrocytes increases 
in vitro myelination
To examine whether the higher secretion of cholesterol by gmAS-
TRs contribute to enhanced myelination, cholesterol was added to 
the in vitro myelinating cultures that depends on an ASTR feeding 
layer. Upon continuous cholesterol treatment, the percentage of my-
elinated axons did not increase on a feeding layer of wmASTRs or 
gmASTRs at the end point of myelination (Figure 5a and b). Thus, the 
percentage of myelinated axons on wmASTRs was still reduced com-
pared to gmASTRs (wmASTRs 3.5 ± 0.6% vs. gmASTRs 6.4 ± 1.4% 
p = .048). This indicates that the addition of cholesterol did not 
compensate for the lower secretion of cholesterol by wmASTRs or, 
alternatively, that an effect of inhibitory wmASTRs-derived factors 
remained dominant. To test whether cholesterol may be taken up 
by other cell types and is thus not sufficiently supplied to OLGs, 
committed cholesterol biosynthesis was inhibited in both types of 
ASTRs via a shRNA knockdown (kd) of Fdft1 (Figure 2a, kdSQS). As 
a negative control a scrambled shRNA construct was used. qPCR 
analysis revealed a 60%–65% decrease in Fdft1 mRNA levels for 
both wmASTRs and gmASTRs (Figure 5c, wm kdSQS p < .001, gm 
     |  11WERKMAN Et Al.
kdSQS p < .001). In accordance, the cholesterol efflux from kdSQS 
ASTRs was reduced by 25%–40% compared to control and scram-
bled shRNA-transduced ASTRs (Figure 5d wm, kdSQS p = .041, gm 
kdSQS p = .014). Moreover the reduction in cholesterol efflux was 
more prominent in gmASTRs than in wmASTRs. Intracellular choles-
terol levels were unchanged (Figure 5e). Against our expectations, 
the percentage of myelinated axons did not decrease on a feeding 
layer of either kdSQS ASTRs. In fact, a two-fold increase in myeli-
nation was observed on a feeding layer of kdSQS wmASTRs com-
pared to a control wmASTR feeding layer (Figure 5a and f, kdSQS 
wmASTRs, p = .007). Furthermore, wmOPC differentiation and my-
elin membrane formation remained similar upon exposure to ACM 
from both kdSQS gmASTRs and kdSQS wmASTRs (Figure 5g and h), 
indicating that cholesterol is not the rate limiting factor and/or other 
factors may compensate for reduced cholesterol levels. Hence, sur-
prisingly, inhibition of committed cholesterol biosynthesis down-
stream of the SQS substrate farnesyl-pyrophosphate (farnesyl-PP) 
in wmASTRs (Figure 2a) promoted, rather than inhibited, in vitro my-
elination. Upon kdSQS, pathways upstream of SQS-mediated con-
version of squalene to ultimately cholesterol, including non-sterol 
isoprenoids and unsaturated fatty acid synthesis (Figure 2a), may 
become more active in kdSQS ASTRs and thereby compensate for 
the effect of reduced cholesterol levels, which was examined next.
3.6 | Inhibition of committed cholesterol 
biosynthesis in white matter astrocytes increases 
Sreb1fc mRNA levels and substantially decreases pro-
IL1β secretion
To examine whether an inhibition of cholesterol synthesis down-
stream of farnesyl-PP results in an increase in fatty acid synthesis 
(Figure 2a), the mRNA levels of Srebf1c were examined by qPCR. An 
increase in Srebf1c transcripts was observed in kdSQS wmASTRs 
compared to control wmASTRs (Figure 6a, p = .013), indicating 
that unsaturated fatty acid production may be increased in kdSQS 
wmASTRs. mRNA levels of Srebf1c were similar in control gmAS-
TRs and kdSQS gmASTRs (Figure 6a). Transcripts of Fasn were not 
significantly changed in kdSQS wmASTRs and kdSQS gmASTRs 
(Figure 6b). Like committed cholesterol biosynthesis, the generation 
of non-sterol isoprenoids is also a downstream pathway of farnesyl-
PP (Veluthakal, Arora, Goalstone, Kowluru, & Kowluru, 2016) 
(Figure 2a). Of note, non-sterol isoprenoids are hydrocarbon chains 
used to anchor several signaling proteins to cell membranes, a 
process called isoprenylation (Caraglia et al., 2005; Lindholm & 
Nilsson, 2007). Interestingly, when blocking cholesterol biosynthe-
sis pathway upstream of farnesyl-PP with the HMG-CoA reductase 
inhibitor simvastatin (Figure 2a), the secretion of several cytokines, 
including IL1β, is increased by inhibition of isoprenylation-depend-
ent signaling pathways (Lindholm & Nilsson, 2007; Massonnet 
et al., 2009). In line with these observations, pro-IL1β levels in ACM 
of kdSQS gmASTRs were reduced compared to pro-IL1β levels in 
ACM of control gmASTRs (Figure 6c,d, p = .032). Similarly, pro-IL1β 
levels were substantially, but not significantly, reduced in ACM of 
kdSQS wmASTRs (Figure 6c and d). Notably, active IL1β was not de-
tected in the medium, probably because of its short half-life after 
secretion (Kudo, Mizuno, Hirai, & Shimizu, 1990). Hence, impairing 
committed cholesterol biosynthesis in wmASTRs enhanced in vitro 
myelination, likely by increased unsaturated fatty acid biosynthesis, 
as well as non-sterol isoprenoid biosynthesis.
4  | DISCUSSION
It is known that remyelination is not only more efficient in GM MS le-
sions than in WM MS lesions (Chang et al., 2012; Strijbis et al., 2017), 
but also faster in GM than in WM upon toxin-induced demyelination 
(Bai et al., 2016). ASTRs are important players in the remyelination 
F I G U R E  3   A mixture of pro-inflammatory cytokines reduces cholesterol efflux from grey and white matter astrocytes. Primary neonatal 
grey matter (gm) and white matter (wm) astrocytes (ASTRs) were either untreated (ctrl) or treated for 24 hr with TLR4 agonist LPS (200 ng/
ml), TLR3 agonist Poly(I:C) (50 μg/ml), or a mixture of pro-inflammatory cytokines consisting of IL1β (1 ng/ml), IFNγ (500 U/ml) and TNFα 
(10 ng/ml). (a) Cholesterol assays on gmASTRs and wmASTRs. Relative cholesterol efflux is shown in (a) and intracellular cholesterol levels, 
shown as intracellular cholesterol/phosphate ratios of gmASTRs and wmASTRs, in (b) (n = 4–15 independent cell culture preparations). 
Note that treatment of gmASTRs with LPS (p = .033) as well as treatment of both types of ASTRs with the pro-inflammatory cytokine mix 
(wmASTRs p = .001; gmASTRs p ≤ 0.001) results in a decrease of cholesterol efflux, while intracellular cholesterol levels are not changed. 
(c and d) Neonatal wmOPCs were differentiated for three days in the presence of ASTR-conditioned medium (ACM) from untreated and 
cytokine (mixture)-treated gmASTRs or wmASTRs. Myelin basic protein (MBP) immunocytochemistry is performed to assess differentiation 
(c, % MBP-positive cells of DAPI-stained cells) and myelin membrane formation (d, % myelin membranes formed by MBP-positive cells; n = 3 
independent cell culture preparations). Note that myelin membrane formation upon exposure to gmACM, but not to wmACM, is substantially 
reduced upon cytokine treatment of gmASTRs (p = .139, not significant). (e–h) mRNA levels of Srebf2 (e), Fdft1 (f), Srebf1c (g) or Fasn (h) 
in gmASTRs and wmASTRs that were either untreated (ctrl) or treated with a mixture of IL1β, IFNγ and TNFα for 24 hr (qPCR analysis of 
n = 3–4 independent cell culture preparations). Note that exposure to the pro-inflammatory cytokine mix decreases transcripts for Srebf1c 
in wmASTRs and gmASTRs (wmASTRs p = .048, gmASTRs p = .008) and for Fasn in gmASTRs (p < .001). Bars represent relative means 
compared to exposure to control wmACM or gmACM (c and d) or untreated (ctrl) gmASTRs or wmASTRs (e–h), which are set to 1 in each 
independent experiment. Error bars represent standard error of the mean (SEM). Statistical analyses are performed using column statistics 
with a one-sample t-test (*p < .05, **p < .01, ***p < .001) to test for differences with control wmACM or gmACM (c and d) or untreated 
(ctrl) gmASTRs or wmASTRs (e–h). Absolute values of OPC differentiation with control wmACM are 21.8 ± 8.9% and with control gmACM 
30.0 ± 8.3%. Absolute values of myelin membrane formation with control wmACM are 59.7 ± 8.3% and with control gmACM 70.5 ± 12.0%
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process, and malfunction of ASTR signaling contributes to remyelina-
tion failure in WM MS lesions (Gutowski, Newcombe, & Cuzner, 1999; 
Harlow & Macklin, 2014; Lau et al., 2012; Lundgaard, Osório, Kress, 
Sanggaard, & Nedergaard, 2014; Stoffels et al., 2013). Therefore, we 
hypothesized that in addition to wmASTRs being more detrimental, 
gmASTRs may be more supportive for remyelination by supplying 
more cholesterol to developing OLGs. Our findings demonstrate 
that cholesterol efflux from gmASTRs was higher than from wmAS-
TRs. This increase in cholesterol secretion correlated with enhanced 
wmOPC differentiation upon exposure to gmACM, but not wmACM, 
and a more supportive role of gmASTRs than wmASTRs in in vitro 
myelination. Although inhibition of committed cholesterol synthe-
sis by a knockdown of SQS reduced cholesterol efflux from ASTRs, 
in vitro myelination remained similar on a feeding layer of kdSQS 
gmASTRs. Moreover, in vitro myelination was enhanced on a feeding 
layer of kdSQS wmASTRs. Hence, cholesterol supply by ASTRs is not 
rate-limiting for in vitro myelination, and more importantly, our find-
ings demonstrated that specific blocking of cholesterol biosynthesis 
in wmASTRs was in fact beneficial for in vitro myelination. This may 
open new ASTRs-based therapeutic strategies that aim to promote 
remyelination in WM MS lesions.
Against our expectations, in vitro myelination was enhanced 
upon reduction of committed cholesterol biosynthesis by a 
knockdown of SQS in wmASTRs, indicating that other factors 
likely masked the effect of reduced levels of ASTR-derived cho-
lesterol. Cholesterol, non-sterol isoprenoids and unsaturated 
fatty acids have acetyl-CoA as a common precursor making their 
synthesis intertwined and tightly coordinated by the SREBP 
F I G U R E  4   Pro-inflammatory cytokines inhibit cholesterol efflux from astrocytes via an ABCA1-dependent pathway. Primary neonatal 
grey matter (gm) and white matter (wm) astrocytes (ASTRs) were either untreated (ctrl) or treated for 24 hr with a mixture of pro-
inflammatory cytokines consisting of IL1β (1 ng/ml), IFNγ (500 U/mL) and TNFα (10 ng/ml) in the absence or presence of ABCA1 inhibitor 
glibenclamide (gli; 0.1 mM) or ABCG1 inhibitor thyroxine (T4; 50 µM). Inhibitors which were added to the cells one hour prior to addition 
of cytokines. (a,b) Cholesterol assays on gmASTRs and wmASTRs. Relative cholesterol efflux is shown in (a) and intracellular cholesterol 
levels, shown as intracellular cholesterol/phosphate ratios, in (b) (n = 3–4 independent cell culture preparations). Note that glibenclamide 
counteracts the cytokine-induced reduction in cholesterol efflux from both wmASTRs and gmASTRs. (c–e) Western blot analyses of 
cholesterol transporters cholesterol transporters ABCA1 and ABCG1. Actin served as a loading control. Representative blots are shown in 
(c) and quantification for ABCA1 in (d) and for ABCG1 in (e) (n = 5–6 independent cell culture preparations). Note that exposure to cytokines 
decreases ABCA1 expression (p < .001) and increases ABCG1 expression (p = .004) in gmASTRs. Bars represent absolute values (b) or 
relative means (c,d,e) compared to control gmASTRs or wmASTRs, which are set to 1 in each independent experiment. Error bars represent 
standard error of the mean (SEM). Statistical analyses are performed using column statistics with a one-sample t-test (*p < .05, **p < .01, 
***p < .001) to test for differences between control gmASTRs or wmASTRs. A one-way ANOVA with a Šidák multiple comparisons post-test 
(#p < .05) is used to test for differences between different treatments
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family of transcription factors (Figure 2a). Our findings revealed 
that transcripts of Sreb1fc, which activates unsaturated fatty 
acid biosynthesis, were increased in kdSQS wmASTRs but not 
in kdSQS gmASTRs compared to control ASTRs. As addition of 
polyunsaturated fatty acids promotes OPC differentiation (van 
Meeteren, Baron, Beermann, Dijkstra, & van Tol, 2006), increased 
unsaturated fatty acid biosynthesis may contribute the observed 
enhanced in vitro myelination upon a feeding layer of kdSQS 
wmASTRs. In addition, a previous study showed that upon re-
stricting synthesis of both cholesterol and non-sterol isoprenoids 
in macrophages by the HMG-CoA reductase inhibitor simvasta-
tin, the secretion of IL1β and IL8 increases, while the secretion 
of TNFα decreases, through an isoprenylation-dependent mech-
anism (Lindholm & Nilsson, 2007). In line with these findings, 
upon specific blocking of cholesterol biosynthesis in ASTRs, as 
established here with kdSQS, more substrate likely became avail-
able for non-sterol isoprenoid synthesis, which may explain the 
reduced pro-IL1β secretion from kdSQS ASTRs. Although find-
ings on IL1β affecting OPC differentiation are conflicting (Vela, 
Molina-Holgado, Arévalo-Martín, Almazán, & Guaza, 2002; Xie 
et al., 2016), IL1β inhibits wmOPC differentiation in vivo (Xie 
et al., 2016). This indicates that statin-mediated inhibition of re-
myelination in the corpus callosum (Klopfleisch et al., 2008; Miron 
et al., 2009) may also be in part unrelated to cholesterol produc-
tion and linked to altered ASTR reactivity and secretome as a re-
sult of reduced non-sterol isoprenoid synthesis. Indeed, statins 
induce an astroglia and microglia response in the demyelinated 
corpus callosum, which hints to alterations in the inflammatory 
environment (Miron et al., 2009). Hence, both enhanced unsatu-
rated fatty acid synthesis and non-sterol isoprenoid biosynthesis 
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in ASTRs, the latter likely resulting in increased isoprenylation 
and the subsequent reduced secretion of ASTR-derived cytokines 
that affect OPC maturation, may contribute to enhanced in vitro 
myelination in the presence of kdSQS wmASTRs despite reduced 
cholesterol levels.
In line with the present findings, differences between GM and 
WM myelination upon inhibition of lipid biosynthesis in ASTRs 
has been described. ASTR specific deletion of SREBP-cleavage-
activating protein (SCAP) that post-transcriptionally activates 
SREBPs (Shimano & Sato, 2017) results in a decrease of WM vol-
ume of approximately 60%, while the reduction in GM was only 
10% (Camargo et al., 2017; Lindholm & Nilsson, 2007; Massonnet 
et al., 2009; Xie et al., 2016). Whether this is because of the lower 
amount of myelin present in GM or that wmOPC differentiation, 
as observed in the present study, is more affected by the reduced 
synthesis of ASTR-derived lipids is not studied yet. Similarly, 
hypomyelination in WM but not in GM may partially relate to 
reduced biosynthesis of non-sterol isoprenoids. As a result, in-
creased secretion of several ASTR-derived cytokines may delay 
and/or reduce wmOPC differentiation and myelination (Camargo 
et al., 2017; Lindholm & Nilsson, 2007; Massonnet et al., 2009; 
Xie et al., 2016). In fact, wmOPC differentiation may depend more 
on secreted factors from ASTRs than gmOPC differentiation, 
including cholesterol, and wmOPCs are more susceptible to the 
effect of pro-inflammatory cytokines than gmOPCs (Lentferink 
et al., 2018). Of relevance, upon SQS deletion in OLGs, which 
makes OLGs dependent on cholesterol supply by other cells, my-
elin appears of normal thickness in GM, whereas it is very thin 
in WM (Saher et al., 2005). Although it cannot be excluded that 
this regional difference in the involvement of cholesterol in my-
elin membrane growth depends on an intrinsic difference between 
gmOPCs and wmOPCs, it is likely that a higher cholesterol efflux 
from gmASTRs, as is suggested (Saher et al., 2005) and shown 
here, is involved.
Our findings indicate that cholesterol efflux from gmASTRs 
and wmASTRs is regulated by inflammatory mediators. While 
TLR4 agonist LPS more potently decreased cholesterol efflux 
from gmASTRs than from wmASTRs, a mixture of pro-inflamma-
tory cytokines decreased cholesterol efflux from both ASTR types 
to a similar extent. However, only secreted factors from cyto-
kine-treated gmASTRs reproducibly decreased myelin membrane 
formation. Hence, the remaining cholesterol levels were sufficient 
and not rate-limiting for OPC differentiation in vitro. Remarkably, 
Srebf2 and Fdft1 mRNA levels were not reduced by cytokine 
treatment of gmASTRs and wmASTRs, indicating that cytokines 
may interfere with the expression and/or function of cholesterol 
transporters. Indeed, ABCA1 expression and cholesterol efflux via 
ABCA1 were reduced in cytokine-treated gmASTRs. Besides, the 
increased ABCG1 expression in cytokine-treated gmASTRs did 
not enhance cholesterol efflux, which is consistent with a previ-
ous study demonstrating that an increased expression of ABCG1 
does not enhance cholesterol efflux per se (Terao et al., 2011). Of 
note, treatment with an ABCA1 agonist increased gene expres-
sion of enzymes involved in cholesterol biosynthesis in ASTRs, and 
improved clinical outcome in experimental autoimmune encepha-
lomyelitis (Itoh et al., 2018). Our results further revealed that ex-
posure to a mixture of pro-inflammatory cytokines reduced mRNA 
levels of Srebf1c in gmASTRs and wmASTRs. In addition, the 
mRNA expression of Fasn was reduced in cytokine-treated gmAS-
TRs, but not in cytokine-treated wmASTRs. Hence, exposure to 
pro-inflammatory cytokines likely interfered with both cholesterol 
efflux and unsaturated fatty acid synthesis. As inflammatory ac-
tivity is lower in GM MS lesions than in WM MS lesions (Chang 
et al., 2012; Clarner et al., 2012; Prins, Schul, Geurts, Valk, & van 
F I G U R E  5   Inhibition of committed cholesterol biosynthesis in white matter astrocytes increases in vitro myelination. (a and b) In vitro 
myelinating cultures that depend on a feeding layer of astrocytes (ASTRs) are obtained from 15 days old rat embryo spinal cord cells and 
either left untreated (ctrl) or treated with 10 μg/ml cholesterol for the duration of the experiment. Cultures were stained for the myelin 
marker myelin basic protein (MBP, green) and the axonal marker neurofilament-H (NF, red). Representative images are shown in (a) and 
quantification of the percentage of myelinated axons in (b) (n = 4 independent cell culture preparations). Note that addition of cholesterol 
does not affect in vitro myelination efficiency of both types of ASTRs. (a and c–e) A lentiviral shRNA knockdown (kd) of Fdft1, encoding 
for squalene synthase (SQS), was established in grey matter (gm)ASTRs and in white matter (wm)ASTRs (kdSQS). A shRNA scrambled 
(scr) construct was used as negative control. mRNA levels of Fdft1 mRNA levels in control (ctrl), scr and kdSQS gmASTRs and wmASTRs 
is shown in (c) (qPCR analysis, n = 6 independent cell culture preparations), cholesterol efflux in (d) and intracellular cholesterol levels, 
shown as intracellular cholesterol/phosphate ratios, in (e) (n = 4 independent culture preparations). Note that Fdft1 mRNA levels (wmASTRs 
and gmASTRs p < .001) and cholesterol efflux (wmASTRs p = .041 and gmASTRs p = .014) are decreased in kdSQS ASTRs. (a and f) In 
vitro myelinating cultures on a feeding layer of ctrl, scr, and kdSQS gmASTRs and wmASTRs. Representative images are shown in (a) and 
quantification of the percentage of myelinated axons in (f) (n = 4 independent cell culture preparations). (g) Neonatal wmOPCs were 
differentiated for three days in the presence of ASTR-conditioned medium (ACM) from control, scr and kdSQS gmASTRs or wmASTRs. MBP 
immunocytochemistry is performed to assess differentiation (% MBP-positive cells of DAPI-stained cells) and myelin membrane formation 
(% myelin membranes formed by MBP-positive cells) (n = 4 independent independent cell culture preparations). Bars represent relative 
means compared to control wmASTRs or gmASTRs (b), which are set to 1 in each independent experiment. Error bars represent standard 
error of the mean (SEM). Statistical analyses are performed using column statistics with a one-sample t-test (*p < .05, **p < .01, ** p < .001) 
to test for differences between control wmASTRs or gmASTRs. Absolute values of the percentage of myelinated axons on a feeding layer of 
control ASTRs are 3.2 ± 0.9% for wmASTRs and 6.7 ± 1.5% for gmASTRs. Absolute values for control ACM of wmASTRs are 20.5 ± 5.4% 
for OPC differentiation and 56.1 ± 7.9% for myelin membrane formation. Absolute values for control ACM of gmASTRs are 23.7 ± 2.4% and 
49.9 ± 9.1%, respectively. Scale bar is 10 µm
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der, Drukarch B., Dam A.-M. van, 2015; Strijbis et al., 2017), the 
cytokine-induced decrease in cholesterol efflux from ASTRs may 
be of more relevance for the reduced remyelination efficiency in 
WM MS lesions.
Taken together, the present study showed a positive correla-
tion between cholesterol secretion and OPC differentiation as 
well as in vitro myelination. However, using the kdSQS in vitro my-
elination model presented in this study, it could not be confirmed 
whether the higher levels of secreted cholesterol by gmASTRs 
play a role in the enhanced myelination efficiency by gmASTRs 
compared to wmASTRs. Intriguingly, using this kdSQS model, we 
identified an under investigated role of non-sterol isoprenoids. 
Non-sterol isoprenoids share a common precursor with the cho-
lesterol and unsaturated fatty acid biosynthesis pathway and 
regulate the secretion of cytokines and in this way contributes 
to ASTR-mediated modulation of OPC differentiation and myelin 
membrane formation. Of interest, from a translational perspec-
tive, interfering with lipid metabolism in ASTRs, that is, increasing 
non-sterol isoprenoid synthesis without interfering with choles-
terol biosynthesis, may be a novel strategy to reduce the secre-
tion of ASTR-derived pro-inflammatory cytokines and to promote 
remyelination in WM MS lesions. Indeed, a lipid-enriched diet is 
sufficient to rescue hypomyelination and neurological deficits in 
conditional SCAP-/- ASTR mice (Camargo et al., 2012, 2017) and 
addition of dietary cholesterol accelerates WM remyelination 
upon toxin-induced demyelination (Berghoff et al., 2017). Hence, 
an increased lipid supply is beneficial for remyelination, and may 
act on SREBPs in ASTRs, thereby likely modulating non-sterol iso-
prenoid synthesis as well.
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